Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVV858 alone and with endocrine therapy in advanced HR-positive/HER2-negative breast cancer and other solid tumors
2025-521911-38-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of GVV858 in breast cancer, ovarian cancer, gastric adenocarcinoma and 3 more (3 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability. Planned start Apr 2026; status: authorised.
02
Drugs
GVV858
03
Conditions
breast cancerovarian cancergastric adenocarcinomaesophageal adenocarcinoma (EAC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2025-521911-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521911-38-00.